



PRODUCT: **TEPEZZA® (teprotumumab-trbw)**

COMPANY: Horizon Therapeutics

THERAPEUTIC AREA & INDICATION:
Treatment of Thyroid Eye Disease (TED)

ABOUT THE PRODUCT

TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) indicated for the treatment of Thyroid Eye Disease (TED). TEPEZZA is the first and only FDA-approved medicine to treat TED, a serious, progressive and vision-threatening rare autoimmune disease. People living with TED often experience long-term functional, psychosocial and economic burdens, including inability to work and perform activities of daily living. TEPEZZA treats TED at the source – a first for patients and doctors. As an infused biologic, TEPEZZA completely changed how physicians treat patients living with TED.